ALDX - アルデイラ・セラピュ―ティクス (Aldeyra Therapeutics Inc.) アルデイラ・セラピュ―ティクス

 ALDXのチャート


 ALDXの企業情報

symbol ALDx
会社名 Aldeyra Therapeutics Inc (アルデイラ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アルディラ・セラピューティックス(Aldeyra Therapeutics Inc)はバイオテクノロジー企業である。同社は主に、遊離アルデヒドとして知られている天然に存在する毒性の化学種に関連すると考えられている免疫介在性、炎症性、希少疾病及び他の疾患を治療する製品の開発に集中する。NS2は、シェーグレン・ラーション症候群(SLS)、円板状エリテマトーデス、急性前部ぶどう膜炎及びマイボーム腺機能不全を伴う紅斑性酒さを含む疾患の治療のために、遊離アルデヒドの捕集・処分を可能にされている製品候補である。同社はまた、NS2と異なるアルデヒドトラップを開発している。平成26年4月7日現在、同社は48人のボランティアでの第I相臨床試験におけるNS2を評価した。   アルデイラ・セラピュ―ティクスは、米国のバイオテクノロジ―企業。アルデヒド類など有毒な化学種の発生によるものと考えられる免疫介在疾患、炎症性疾患、奇病およびその他の疾患向けに、新製品の開発を行う。アルデヒドを除去できる製品を開発し、シェ―グレン・ラ―ション症候群の治療薬NS2の製品候補としてのテストを行う。   
本社所在地 131 Hartwell Avenue Suite 320 Lexington MA 02421 USA
代表者氏名 Todd C. Brady トッドC.ブラディ
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 781-761-4904
設立年月日 38200
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数
url www.aldeyra.com
nasdaq_url https://www.nasdaq.com/symbol/aldx
adr_tso
EBITDA EBITDA(百万ドル) -29.67208
終値(lastsale) 12.8
時価総額(marketcap) 268478976
時価総額 時価総額(百万ドル) 332.67550
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 292.34136
当期純利益 当期純利益(百万ドル) -29.38821
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 68% to $17.4M. Higher net loss reflects Interest Exp-Net of Capitalized Interest increase of 2% to $54K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.72 to -$0.89.

 ALDXのテクニカル分析


 ALDXのニュース

   Notable Insider Buys Of The Past Week: Affirm, HEICO, Vector Group, Biotechs And More  2021/01/24 12:12:28 Benzinga
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Insiders have been taking advantage of secondary and initial public offerings recently. Biotech companies are once again well represented on this list of notable insider share purchases. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets. Note that with earnings reporting season in full swing, buy windows for many insiders are closed. Here are some of the most noteworthy insider purchases that were reported in the past week. Biotech company Aldeyra Therapeutics Inc (NASDAQ: ALDX ) saw a 10% owner return and add almost 1.37 million shares to its stake. At a secondary offering price of $9.50 per share, the transaction totaled about $13 million.
   Thinking about buying stock in Aemetis, Aldeyra Therapeutics, Seelos Therapeutics, INmune Bio, or O2Micro International?  2021/01/22 14:31:00 PR Newswire
NEW YORK, Jan. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMTX, ALDX, SEEL, INMB, and OIIM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares  2021/01/20 12:00:00 Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the pot
   Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock  2021/01/14 02:36:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwritten public offering of 6,842,106 shares of its common stock at a public offering price of $9.50 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions
   Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock  2021/01/13 21:01:00 Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the pot
   Aldeyra Therapeutics Announces Initiation of Phase 2 Clinical Trials of ADX-629, a First-in-Class Orally Administered RASP Inhibitor, for the Treatment of COVID-19, Atopic Asthma, and Psoriasis  2020/12/17 13:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administered reactive aldehyde species (RASP) inhibitor, for the treatment of COVID-19, atopic asthma, and psoriasis as part of a systematic strategy to assess activity across different types of immunological diseases. The Phase 2 clinical trials follow a successful Phase 1 clinical trial of ADX-629, which demonstrat
   Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease  2020/12/08 13:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced enrollment of the first patient in the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease. The multi-center randomized, double-masked, parallel design, vehicle-controlled clin
   Aldeyra Therapeutics to Participate in the Jefferies and A.G.P./Alliance Global Partners Virtual Investor Conferences  2020/11/13 13:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the company’s senior management will participate in the following virtual investor conferences: Jefferies Virtual London Healthcare Conference: Aldeyra President and CEO Todd C. Brady, M.D., Ph.D., is scheduled to participate in a fireside chat at 1:10 p.m. ET on Wednesday, November 18, 2020. The fireside chat will be broadcast live and archived for 90 days on the company’s website at htt
   Aldeyra Therapeutics Announces Third-Quarter 2020 Financial Results and Provides Corporate Update  2020/11/05 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced financial results for the third quarter of 2020 and provided a corporate update. “Our novel RASP inhibitor reproxalap continues to progress toward New Drug Application (NDA) submissions for dry eye disease and allergic conjunct
   Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6  2020/11/04 13:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra’s novel therapeutic approaches to treating anterior and posterior segment ocular disease at the Eyecelerator 2020 Virtual Conference on Friday, November 6, 2020. Dr. Brady’s presentation is scheduled begin at 1:19 p.m. PT / 4:19 p.m. ET as part of Company Showcase III, “Advancing Trials in the Public Eye.” The presentation
   Aldeyra to Participate in the American Academy of Ophthalmology Eyecelerator 2020 Virtual Conference on Friday, November 6  2020/11/04 13:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and CEO Todd C. Brady, M.D., Ph.D., will discuss Aldeyra’s novel therapeutic approaches to treating anterior and posterior segment ocular disease at the Eyecelerator 2020 Virtual Conference on Friday, November 6, 2020. Dr. Brady’s presentation is scheduled begin at 1:19 p.m. PT / 4:19 p.m. ET as part of Company Showcase III, “Advancing Trials in the Public Eye.” The presentation
   Aldeyra Has 'Catalayst-Rich' 12 Months Ahead, Jefferies Says In Bullish Initiation  2020/10/31 01:22:24 Benzinga
Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX ), a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst. The Aldeyra Analyst: Kelly Shi initiated coverage of Aldeyra shares with a Buy rating and $24 price target. The Aldeyra Thesis: Aldeyra's lead asset reproxalap has substantial opportunity in ocular inflammatory dry eye disease and allergic conjunctivitis, Shi said in a Friday initiation note. With market dominant brands such as Allergan's Restasis and Novartis AG's (NYSE: NVS ) Xiidra having pitfalls such as … Full story available on Benzinga.com
   Aldeyra Therapeutics (NASDAQ:ALDX) Trading Up 6.9%  2020/10/22 19:26:41 US Banking News
Aldeyra Therapeutics, Inc (NASDAQ:ALDX)’s share price was up 6.9% during trading on Thursday . The company traded as high as $7.68 and last traded at $7.59. Approximately 753,584 shares traded hands during trading, an increase of 4% from the average daily volume of 726,544 shares. The stock had previously closed at $7.10. A number of […]
   Aldeyra to Present New Reproxalap Data from Phase 2 Clinical Trial in Allergic Conjunctivitis at American Academy of Ophthalmology 2020 Annual Meeting  2020/10/22 12:00:00 Business Wire
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will present new data from the Phase 2 allergen chamber clinical trial of reproxalap ophthalmic solution (0.25% and 0.5%) in allergic conjunctivitis. The data will be presented in a poster at the American Academy of Ophthalmology 2020 Virtual Annual Meeting (AAO 2020) from November 11 through November 15, 2020. In the randomized, double-masked, crossover, vehicle-controlled Phase 2 cli
   Aldeyra Therapeutics (NASDAQ:ALDX) Trading Down 6.3%  2020/10/21 19:38:47 The Olympia Report
Aldeyra Therapeutics, Inc (NASDAQ:ALDX)’s stock price fell 6.3% on Wednesday . The stock traded as low as $7.05 and last traded at $7.10. 804,320 shares were traded during trading, an increase of 11% from the average session volume of 726,400 shares. The stock had previously closed at $7.58. ALDX has been the subject of several […]

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルデイラ・セラピュ―ティクス ALDX Aldeyra Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)